Axa S.A. decreased its holdings in shares of Colgate-Palmolive (NYSE:CL – Free Report) by 38.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 436,996 shares of the company’s stock after selling 267,403 shares during the quarter. Axa S.A. owned 0.05% of Colgate-Palmolive worth $32,840,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Korea Investment CORP grew its holdings in shares of Colgate-Palmolive by 12.6% during the fourth quarter. Korea Investment CORP now owns 771,326 shares of the company’s stock worth $60,773,000 after purchasing an additional 86,448 shares in the last quarter. TCG Advisory Services LLC purchased a new stake in Colgate-Palmolive in the first quarter worth approximately $207,000. Oregon Public Employees Retirement Fund boosted its stake in Colgate-Palmolive by 1.2% in the first quarter. Oregon Public Employees Retirement Fund now owns 64,475 shares of the company’s stock worth $4,845,000 after buying an additional 735 shares in the last quarter. Profund Advisors LLC boosted its stake in Colgate-Palmolive by 20.6% in the first quarter. Profund Advisors LLC now owns 11,093 shares of the company’s stock worth $834,000 after buying an additional 1,897 shares in the last quarter. Finally, Cyndeo Wealth Partners LLC boosted its stake in Colgate-Palmolive by 1.8% in the first quarter. Cyndeo Wealth Partners LLC now owns 11,525 shares of the company’s stock worth $48,000 after buying an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 78.36% of the company’s stock.
Analysts Set New Price Targets
A number of analysts have recently weighed in on CL shares. Deutsche Bank Aktiengesellschaft increased their price objective on Colgate-Palmolive from $88.00 to $91.00 and gave the company a “buy” rating in a research note on Monday, July 31st. Royal Bank of Canada restated a “sector perform” rating and set a $83.00 target price on shares of Colgate-Palmolive in a report on Monday, July 31st. StockNews.com downgraded Colgate-Palmolive from a “buy” rating to a “hold” rating in a report on Saturday, September 2nd. Finally, Barclays upped their target price on Colgate-Palmolive from $77.00 to $81.00 and gave the company an “equal weight” rating in a report on Tuesday, August 1st. Five research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, Colgate-Palmolive has an average rating of “Moderate Buy” and a consensus price target of $85.33.
Insider Activity at Colgate-Palmolive
In other Colgate-Palmolive news, insider John W. Kooyman sold 21,677 shares of the firm’s stock in a transaction dated Wednesday, August 2nd. The stock was sold at an average price of $77.69, for a total value of $1,684,086.13. Following the transaction, the insider now directly owns 6,384 shares of the company’s stock, valued at $495,972.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, VP Gregory Malcolm sold 10,493 shares of the firm’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $73.90, for a total value of $775,432.70. Following the transaction, the vice president now owns 7,852 shares of the company’s stock, valued at $580,262.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider John W. Kooyman sold 21,677 shares of the firm’s stock in a transaction dated Wednesday, August 2nd. The stock was sold at an average price of $77.69, for a total value of $1,684,086.13. Following the completion of the transaction, the insider now directly owns 6,384 shares in the company, valued at approximately $495,972.96. The disclosure for this sale can be found here. 0.34% of the stock is currently owned by insiders.
Colgate-Palmolive Trading Down 0.5 %
NYSE CL opened at $73.20 on Monday. Colgate-Palmolive has a 12 month low of $67.84 and a 12 month high of $82.09. The stock has a market cap of $60.51 billion, a P/E ratio of 40.67, a P/E/G ratio of 3.13 and a beta of 0.50. The stock’s fifty day moving average price is $75.42 and its 200-day moving average price is $75.85. The company has a current ratio of 1.17, a quick ratio of 0.73 and a debt-to-equity ratio of 28.43.
Colgate-Palmolive (NYSE:CL – Get Free Report) last released its quarterly earnings data on Friday, July 28th. The company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.75 by $0.02. Colgate-Palmolive had a return on equity of 386.76% and a net margin of 8.02%. The company had revenue of $4.82 billion for the quarter, compared to analysts’ expectations of $4.70 billion. During the same period last year, the firm posted $0.72 earnings per share. Colgate-Palmolive’s revenue was up 7.5% compared to the same quarter last year. As a group, equities analysts forecast that Colgate-Palmolive will post 3.17 EPS for the current fiscal year.
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.
- Five stocks we like better than Colgate-Palmolive
- How to Start Investing in Real Estate
- MarketBeat Week in Review – 9/4 – 9/8
- What Are Dividend Champions? How to Invest in the Champions
- The Best 5 Small Cap AI Companies to Buy Now
- Insider Buying Explained: What Investors Need to Know
- Miso Robotics Stock: Is an IPO Coming Soon?
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.